Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause.

ABSTRACT: The most common symptom of menopause is vasomotor symptoms (VMS), which occur in more than 80% of postmenopausal women. Furthermore, VMS are the manifestation of menopause for which women most commonly seek treatment, namely, to address their impacted quality of life, including sleep, and work-and non-work-related productivity. VMS vary in frequency, intensity and duration. Hormone therapy (HT) has been our most effective treatment for VMS and has been approved for this indication by the United States Food and Drug Administration (FDA). Despite being a safe and effective treatment option, many patients and providers are hesitant to consider HT. Moreover, HT is contraindicated for some women. While many over-the-counter and non-HT options are available, we lack data on the efficacy and safe

SUBMITTER: DePree B 

PROVIDER: S-EPMC10769482 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature